Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

EMA – New stem cell therapy to treat patients with blood cancers

EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Zemcelpro (dorocubicel / unexpanded umbilical cord cells) to treat adults with haematological malignancies (blood cell cancers). Zemcelpro can be used in patients requiring an allogeneic haematopoietic stem cell transplantation (allo-HSCT, transplantation of stems cell from a donor) following myeloablative conditioning (chemotherapy and/or radiotherapy) for whom no other type of suitable donor cells is available.

Haematological malignancies are blood cell cancers categorised depending on where they are first detected and include leukaemias (blood), lymphomas (lymph nodes), myelodysplastic syndrome and myelomas (bone marrow). They are frequently diagnosed cancers, and the only potential curative treatment option for several of these cancers is allo-HSCT. This type of transplant involves using donated stem cells to replace the recipient’s bone marrow cells to form new bone marrow that produces healthy blood cells.

More information on the EMA Website.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (28 juillet 2025). EMA – New stem cell therapy to treat patients with blood cancers. ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/14fy5


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.